GDF3 is an endogenous antagonist of the ActE-ALK7/ACVR2 pathway in adipocytes. (PubMed, bioRxiv) - Oct 2, 2026 - "Gdf3 deficiency synergized with the clinical-stage anti-activin receptor antibody Bimagrumab to amplify fat-mass loss and improve glucose homeostasis in multiple MASH models. These findings establish GDF3 as an endogenous antagonist of ActE-ALK7 signaling and nominate GDF3 inhibition as a therapeutic strategy for MASLD/MASH."
Journal • Diabetes • Fibrosis • Genetic Disorders • Hematological Disorders • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Type 2 Diabetes Mellitus • ACVR2A • TGFB1
|
|
Alexander S Banks; Cadence J Vieira; Deepti Ramachandran; Evelyn Y Zhou; Henning F Kramer; James A Howard; Josep M Mercader; Kyung Cheul Shin; Nagasuryaprasad Kotikalapudi; Paul M Titchenell; Sarah Hsu; Shirish Naz; Stephen E Flaherty; Thomas B Thompson; Wei-An Chen; Zhenghui Gordon Jiang
|